In Q2 2025, Capricor Therapeutics posted a net loss of $25.9M or $0.57 per share, driven by increased operating expenses and no reported revenue. Cash balance at the end of the quarter was $122.8M, expected to fund operations into Q4 2026.
No revenue was reported in Q2 2025, down from $4.0M in Q2 2024
Net loss was $25.9M, or $0.57 per share
Operating expenses rose to $27.7M due to higher R&D and G&A costs
Cash balance stood at $122.8M, expected to fund operations into Q4 2026
Capricor expects current cash resources to fund operations through Q4 2026, excluding potential milestone payments.
Analyze how earnings announcements historically affect stock price performance